5T
511 Therapeutics, Inc.
SEC filingBiotechnology · Cambridge, MA
Amount raised$500Ksold at filing
Total offering$1M$500K still open
Investors in the raise1count reported to the SEC
FiledOct 30, 2026first sale Oct 21, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Shuguang ZhangExecutive Officer, Director
Yancen LuDirector
Uwe B. SleytrDirector
Andrew MarshallExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.